Differential impact of fentanyl and morphine doses on ticagrelor-induced platelet inhibition in ST-segment elevation myocardial infarction: a subgroup analysis from the PERSEUS randomized trial

Differential impact of fentanyl and morphine doses on ticagrelor-induced platelet inhibition in ST-segment elevation myocardial infarction: a subgroup analysis from the PERSEUS randomized trial

IntroductionAmong patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI), intravenous fentanyl does not enhance ticagrelor-induced platelet inhibition within 2 h compared to morphine. The impact of the total dose of fentanyl and...

Full description

Bibliographic Details
Main Authors:	Dorian Garin, Sophie Degrauwe, Federico Carbone, Yazan Musayeb, Nathalie Lauriers, Marco Valgimigli, Juan F. Iglesias
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-04-01
Series:	Frontiers in Cardiovascular Medicine
Subjects:	fentanyl dose pharmacodynamics pharmacokinetics ST-segment elevation myocardial infarction ticagrelor
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2024.1324641/full

Similar Items

Clinical Pharmacology of Fentanyl in Preterm Infants. A Review
by: Gian Maria Pacifici
Published: (2015-06-01)

The pharmacokinetics and pharmacodynamics of fentanyl administered via transdermal patch in horses
by: Rachel A. Reed, et al.
Published: (2024-03-01)

Evaluation of pharmacokinetic, pharmacodynamic, efficacy, and safety data of low-dose ticagrelor versus standard dose in East Asians: a systematic review
by: Lee YJ, et al.
Published: (2018-01-01)

Developing mathematical models to compare and analyse the pharmacokinetics of morphine and fentanyl
by: Prathvi Shenoy, et al.
Published: (2024-01-01)

Pharmacokinetic Modeling of Morphine’s Effect on Plasma Concentrations of Ticagrelor and Its Metabolite in Healthy Volunteers
by: Katarzyna Buszko, et al.
Published: (2021-06-01)

Pharmacokinetics, Bioequivalence and Safety Evaluation of Two Ticagrelor Tablets Under Fasting and Fed Conditions in Healthy Chinese Subjects
by: Wang J, et al.
Published: (2021-03-01)

Cangrelor in contemporary patients with ST-segment elevation myocardial infarction pretreated with Ticagrelor: Pharmacodynamic data from the POMPEII study
by: Giuseppe Gargiulo, et al.
Published: (2024-02-01)

Ticagrelor and thrombolysis in myocardial infarction: what does the TREAT study change?
by: O. V. Averkov, et al.
Published: (2018-09-01)

Bioequivalence study of ticagrelor in normal, healthy Indian subjects under fasting conditions: A randomized, blinded, crossover study
by: T Pavan Pradeep, et al.
Published: (2023-01-01)

Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial
by: Cai-De Jin, et al.
Published: (2021-06-01)

Ticagrelor versus clopidogrel in real-world patients with ST elevation myocardial infarction: 1-year results by propensity score analysis
by: Matteo Vercellino, et al.
Published: (2017-04-01)

Comparison of Postoperative Analgesic Effects of Thoracic Epidural Morphine and Fentanyl
by: Gönül Sağıroğlu
Published: (2011-11-01)

Pharmacokinetic and Pharmacogenetic Factors Contributing to Platelet Function Recovery After Single Dose of Ticagrelor in Healthy Subjects
by: Qian Zhu, et al.
Published: (2019-03-01)

Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis
by: Qiufen Xie, et al.
Published: (2022-03-01)

Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54
by: Marc P. Bonaca, et al.
Published: (2018-11-01)

The Role of Ticagrelor in STEMI Fibrinolytic and Its Rationale to Utilize for Indonesian Patients
by: Daniel Tobing, et al.
Published: (2019-09-01)

Pharmacokinetics of Sublingually Delivered Fentanyl in Head and Neck Cancer Patients Treated with Curatively Aimed Chemo or Bioradiotherapy
by: Evelien J. M. Kuip, et al.
Published: (2018-11-01)

Effect of CYP4F2 Polymorphisms on Ticagrelor Pharmacokinetics in Healthy Chinese Volunteers
by: Shanshan Nie, et al.
Published: (2022-02-01)

Ticagrelor
by: Gianluca Airoldi, et al.
Published: (2013-03-01)

Reacción de hipersensibilidad a ticagrelor
by: Jorge Alberto Castro Clavijo, et al.
Published: (2020-02-01)

Factors Determining Ticagrelor-Induced Dyspnea in Patients with Acute Coronary Syndrome
by: Vytenis Tamakauskas, et al.
Published: (2022-10-01)

Comparison of the Maternal and Neonatal Effects of Intratechal Bupivacaine Plus Fentanyl or Morphine During Cesarean Delivery
by: Ahmet Yıldırım, et al.
Published: (2016-09-01)

A Case Report of Ticagrelor-Induced Thrombocytopenia
by: Alsalman M
Published: (2023-07-01)

Impact of morphine dose on ticagrelor uptake and platelet inhibition in patients with ST-segment elevation myocardial infarction – A substudy from the prospective randomized MOVEMENT trial
by: Manne Holm, et al.
Published: (2021-12-01)

The Effect of Platelet Activity, ABCB1 Genetic Polymorphism, and Renal Function on the Development of Ticagrelor-Related Dyspnea in Patients with Acute Coronary Syndrome
by: Tamakauskas V, et al.
Published: (2024-01-01)

Ticagrelor vs. clopidogrel for coronary microvascular dysfunction in patients with STEMI: a meta-analysis of randomized controlled trials
by: Yike Li, et al.
Published: (2023-05-01)

Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study
by: Francesco Franchi, et al.
Published: (2020-04-01)

Contributions of UDP-Glucuronosyltransferases to Human Hepatic and Intestinal Metabolism of Ticagrelor and Inhibition of UGTs and Cytochrome P450 Enzymes by Ticagrelor and its Glucuronidated Metabolite
by: Shuaibing Liu, et al.
Published: (2021-10-01)

Fentanyl but Not Morphine or Buprenorphine Improves the Severity of Necrotizing Acute Pancreatitis in Rats
by: Emese Réka Bálint, et al.
Published: (2022-01-01)

Efficacy and safety of cangrelor as compared to ticagrelor in patients with ST-elevated myocardial infarction (STEMI): a systematic review and meta-analysis
by: Subhro Chakraborty, et al.
Published: (2024-04-01)

Effect of Ticagrelor, a Cytochrome P450 3A4 Inhibitor, on the Pharmacokinetics of Tadalafil in Rats
by: Young-Guk Na, et al.
Published: (2019-07-01)

INFLUENCE OF SWITCHING OF CLOPIDOGREL TO TICAGRELOR ON THE DEVELOPMENT OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ST SEGMENT ELEVATION
by: E. V. Tavlueva, et al.
Published: (2017-11-01)

Continuous Fentanyl Infusion in Newborns with Hypoxic–Ischemic Encephalopathy Treated with Therapeutic Hypothermia: Background, Aims, and Study Protocol for Time-Concentration Profiles
by: Licia Lugli, et al.
Published: (2023-08-01)

Impact of Crystal Habit on Solubility of Ticagrelor
by: Yan Ren, et al.
Published: (2019-10-01)

Teofilina para o Alívio da Dispneia Relacionada ao Ticagrelor
by: Marcelo Sanmartin-Fernandez, et al.
Published: (2021-07-01)

Pharmacodynamics of Five Anthraquinones (Aloe-emodin, Emodin, Rhein, Chysophanol, and Physcion) and Reciprocal Pharmacokinetic Interaction in Rats with Cerebral Ischemia
by: Rong-Rong Li, et al.
Published: (2019-05-01)

Ticagrelor versus clopidogrel in the management of acute myocardial infarction
by: Candice Volney, et al.
Published: (2019-07-01)

Clinical outcomes with the use of ticagrelor or clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction – A prospective observational study
by: Bibek Agarwal, et al.
Published: (2022-01-01)

Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia
by: Sutep Jaruratanasirikul, et al.
Published: (2015-02-01)

Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers
by: Shijia Liu, et al.
Published: (2017-07-01)